Affordable Access

deepdyve-link
Publisher Website

Daylight photodynamic therapy for the management of actinic cheilitis.

Authors
  • Andreadis, Dimitrios1
  • Pavlou, Achilleia -Maria2
  • Vakirlis, Efstratios3
  • Anagnostou, Eleftherios2
  • Vrani, Fotini3
  • Poulopoulos, Athanasios2
  • Kolokotronis, Alexandros2
  • Ioannidis, Dimitrios3
  • Sotiriou, Elena3
  • 1 Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece. [email protected] , (Greece)
  • 2 Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece. , (Greece)
  • 3 First Dermatology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. , (Greece)
Type
Published Article
Journal
Archives of Dermatological Research
Publisher
Springer-Verlag
Publication Date
Dec 01, 2020
Volume
312
Issue
10
Pages
731–737
Identifiers
DOI: 10.1007/s00403-020-02069-y
PMID: 32266532
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Early identification and adequate treatment of actinic cheilitis (AC), which affects the lower lip vermillion and is considered a precursor of squamous cell carcinoma, is mandatory. Photodynamic therapy (PDT) has been successfully used in AC. PDT with the use of daylight (DLPDT) is equally effective and more convenient than the conventional PDT. Data on short and long-term efficacy of DLPDT in AC are limited. Our primary purpose was to assess efficacy of DLPDT in AC as well as safety and tolerance. Twenty-two individuals with histologically confirmed AC received 2 MAL (5-aminolevulinic acid)-DLPDT sessions 1 week apart. Patients were evaluated clinically 3, 6, and 12 months after treatment. Non-complete responders were biopsied and excluded from the study if histological alterations were indicative of AC. Adverse events were recorded from baseline to the end of the 12-month follow-up period. Twenty patients completed the study. Overall, complete clinical response 12 months after treatment was 80% (16/20), while an association between treatment response and grade of dysplasia was observed (p = 0.016). With respect to response by grade, complete clinical response achieved in grade I AC was 100% (12/12) and 50% (4/8) in grade II AC. Main adverse events included mild erythema, oedema, and scaling, with no pain associated with DLPDT. According to our results, DLPDT seems to be of significant benefit for the treatment of grade I AC. Combination with the other treatment modalities could improve the efficacy in grade II AC. Further studies are needed for the assessment of late recurrences.

Report this publication

Statistics

Seen <100 times